{"Ticker": "HSIC", "Company": "Henry Schein", "Sector": "Health Care", "Updated": "2022-07-21", "Rating": [{"Date": "2022-07-21", "Rating": "Downgrade", "Organization": "Goldman", "Rating_Change": "Buy to Neutral", "Target_Change": "$93 to $85"}, {"Date": "2022-06-14", "Rating": "Downgrade", "Organization": "Robert W. Baird", "Rating_Change": "Outperform to Neutral", "Target_Change": "$103 to $88"}, {"Date": "2022-05-13", "Rating": "Resumed", "Organization": "Credit Suisse", "Rating_Change": "Outperform", "Target_Change": "$100"}, {"Date": "2022-01-31", "Rating": "Initiated", "Organization": "Morgan Stanley", "Rating_Change": "Underweight", "Target_Change": "$67"}, {"Date": "2022-01-07", "Rating": "Upgrade", "Organization": "Credit Suisse", "Rating_Change": "Neutral to Outperform", "Target_Change": "$78 to $90"}, {"Date": "2021-10-01", "Rating": "Resumed", "Organization": "Credit Suisse", "Rating_Change": "Neutral", "Target_Change": "$78"}, {"Date": "2021-02-08", "Rating": "Resumed", "Organization": "Piper Sandler", "Rating_Change": "Overweight", "Target_Change": "$83"}, {"Date": "2021-01-04", "Rating": "Upgrade", "Organization": "Robert W. Baird", "Rating_Change": "Neutral to Outperform", "Target_Change": "$70 to $79"}, {"Date": "2020-11-03", "Rating": "Upgrade", "Organization": "Barrington Research", "Rating_Change": "Mkt Perform to Outperform", "Target_Change": "$72"}, {"Date": "2020-05-06", "Rating": "Downgrade", "Organization": "Barrington Research", "Rating_Change": "Outperform to Mkt Perform", "Target_Change": ""}, {"Date": "2020-04-07", "Rating": "Upgrade", "Organization": "Goldman", "Rating_Change": "Neutral to Buy", "Target_Change": "$64 to $59"}, {"Date": "2020-04-02", "Rating": "Upgrade", "Organization": "Wolfe Research", "Rating_Change": "Peer Perform to Outperform", "Target_Change": "$68"}, {"Date": "2020-01-09", "Rating": "Downgrade", "Organization": "BofA/Merrill", "Rating_Change": "Neutral to Underperform", "Target_Change": ""}, {"Date": "2020-01-02", "Rating": "Upgrade", "Organization": "Evercore ISI", "Rating_Change": "Underperform to In-line", "Target_Change": "$61 to $70"}, {"Date": "2019-08-07", "Rating": "Downgrade", "Organization": "William Blair", "Rating_Change": "Outperform to Mkt Perform", "Target_Change": ""}, {"Date": "2019-05-30", "Rating": "Initiated", "Organization": "Wolfe Research", "Rating_Change": "Underperform", "Target_Change": ""}, {"Date": "2019-05-15", "Rating": "Downgrade", "Organization": "SVB Leerink", "Rating_Change": "Outperform to Mkt Perform", "Target_Change": "$75 to $70"}, {"Date": "2019-04-18", "Rating": "Initiated", "Organization": "Guggenheim", "Rating_Change": "Buy", "Target_Change": ""}, {"Date": "2019-01-17", "Rating": "Initiated", "Organization": "UBS", "Rating_Change": "Sell", "Target_Change": "$73"}, {"Date": "2019-01-03", "Rating": "Downgrade", "Organization": "Evercore ISI", "Rating_Change": "In-line to Underperform", "Target_Change": ""}, {"Date": "2019-01-02", "Rating": "Downgrade", "Organization": "Robert W. Baird", "Rating_Change": "Outperform to Neutral", "Target_Change": ""}, {"Date": "2018-11-08", "Rating": "Reiterated", "Organization": "Barrington Research", "Rating_Change": "Outperform", "Target_Change": "$92 to $96"}, {"Date": "2018-10-25", "Rating": "Downgrade", "Organization": "Edward Jones", "Rating_Change": "Hold to Sell", "Target_Change": ""}, {"Date": "2018-10-19", "Rating": "Resumed", "Organization": "Goldman", "Rating_Change": "Neutral", "Target_Change": ""}, {"Date": "2018-10-04", "Rating": "Reiterated", "Organization": "Robert W. Baird", "Rating_Change": "Outperform", "Target_Change": "$90 to $95"}]}